Biochemical markers of psoriasis as a metabolic disease

Folia Histochemica et Cytobiologica

Volumn 50, Issue 2, 2012, Pages 155-170

  Gerkowicz, Agnieszka ^a   Pietrzak, Aldona ^a   Szepietowski, Jacek Cezary ^b   Radej, Sebastian ^a   Chodorowska, Grazyna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Adipokines; CRP; Cytokines; Metabolic syndrome; PAI 1; Psoriasis; Uric acid

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN B; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GHRELIN; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; URIC ACID;

CYTOKINE PRODUCTION; DISEASE ASSOCIATION; HUMAN; METABOLIC SYNDROME X; MOLECULAR PATHOLOGY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PSORIASIS; REVIEW; RISK FACTOR; URIC ACID BLOOD LEVEL;

EID: 84863870099     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2012.0025     Document Type: Review

References (221)

1. Alsufyani MA, Golant AK, Lebwohl M. Psoriasis and the metabolic syndrome. Dermatol Ther. 2010;23:137-143.
2. Fitch E, Herper E, Schorkeva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis recent advances on IL 23 nad TH 17 cytokines. Curr Rheumatol Rep. 2007;9:461-467.
3. Davidovici BB, Sattar N, Prinz JC et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130:1785-1796.
4. Zhu K, Ye J, Wu M, Cheng H. Expression of Th1 and Th2 cytokine-associated transcription factors, T-bet and GATA-3, in peripheral blood mononuclear cells and skin lesions of patients with psoriasis vulgaris. Arch Dermatol Res. 2010;302:517-523.
5. Antonelli A, Fallahi P, Delle Sedie A et al. High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthtritis. Clin Exp Rheumatol. 2009;27:22-27.
6. Jacob SE, Nassiri M, Kerdel FA, Vincek V. Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediators Inflamm. 2003;12:309-313.
7. Clarke LE, Helm KF, Hennessy J, Bruggeman RD, Clarke JT. Dermal dendritic cells in psoriasis, nummular dermatitis, and normal-appearing skin. J Am Acad Dermatol. 2011 Jun 11. Epub ahead of print.
8. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J et al. Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. J Allergy Clin Immunol. 2007;119:1210-1217.
9. Albanesi C, Scarponi C, Bosisio D, Sozzani S, Girolomoni G. Immune functions and recruitment of plasmacytoid dendritic cells in psoriasis. Autoimmunity. 2010;43:215-219.
10. Khayrullina T, Yen JH, Jing H, Ganea D. In vitro differentiation of dendritic cells in the presence of prostaglandin E2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells. J Immunol. 2008;181:721-735.
11. Tan ZY, Bealgey KW, Fang Y, Gong YM, Bao S. Interleukin- 23: immunological roles and clinical implications. Int J Biochem Cell Biol. 2009;41:733-735.
12. Lombardi V, Van Overtvelt L, Horiot S, Moingeon P. Human dendritic cells stimulated via TLR7 and/or TLR8 induce the sequential production of Il-10, IFN-gamma, and IL-17A by naive CD4+ T cells. J Immunol. 2009;182:3372-3379.
13. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485-517.
14. Zhou L, Lopes JE, Chong MM et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing ROR-t function. Nature. 2008;453:236-240.
15. Chan JR, Blumenschein W, Murphy E et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203:2577-2587.
16. Wolk K, Witte E, Wallace E et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006;36:1309-1323.
17. Wilson NJ, Boniface K, Chan JR et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8:950-957.
18. Zaba LC, Cardinale I, Gilleaudeau P et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204:3183-3194.
19. Kryczek I, Bruce AT, Gudjonsson JE et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol. 2008;181:4733-4741.
20. Lowes MA, Kikuchi T, Fuentes-Duculan J et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128:1207-1211.
21. Harper EG, Guo C, Rizzo H et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol. 2009;129:2175-2183.
22. Nograles KE, Zaba LC, Shemer A et al. IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing T(H)17 T cells. J Allergy Clin Immunol. 2009;123:1244-1251e2.
23. Nograles KE, Zaba LC, Guttman-Yassky E et al. Th17 cytokines, interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159:1092-1102.
24. Zhang N, Pan HF, Ye DQ. Th22 in inflammatory and autoimmune disease: prospects for therapeutic intervention. Mol Cell Biochem. 2011;353:41-46.
25. Fujita H, Nograles KE, Kikuchi T, Gonzalez J, Carucci JA, Krueger JG. Human Langerhans cells induce distinct IL-22- -producing CD4+ T cells lacking IL-17 production. Proc Natl Acad Sci USA. 2009;106:21795-21800.
26. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866-873.
27. Guttman-Yassky E, Krueger JG. Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research. Br J Dermatol. 2007;157:1103-1115.
28. Taams L, Vukmanovic-Stejic M, Salmon M, Akbar A. Immune regulation by CD4+CD25+ regulatory T cells: implications for transplantation tolerance. Transpl Immunol. 2003;11:277-285.
29. Mutis T, Aarts-Riemens T, Verdonck LF. The association of CD25 expression on donor CD8+ and CD4+ T cells with graftversus- host disease after donor lymphocyte infusions. Haematologica. 2005;90:1389-1395.
30. Zorn E, Kim HT, Lee SJ et al. Reduced frequency of FOXP3+ CD4+ CD25+ regulatory T cells in patients with chronic graft- -versus-host disease. Blood. 2005;106:2903-2911.
31. Liyanage UK, Moore TT, Joo HG et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756-2761.
32. Woo EY, Yeh H, Chu CS et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002;168:4272-4276.
33. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6:295-307.
34. Sugiyama H, Gyulai R, Toichi E et al. Dysfunctional blood and target tissue CD4+ CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immuno. 2005;174:164-173.
35. Bovenschen HJ, van Vlijmen-Willems IM, van de Kerkhof PC, van Erp PE. Identification of lesional CD4+ CD25+ Foxp3+ regulatory T cells in Psoriasis. Dermatology. 2006;213:111-117.
36. Cheng X, Yu X, Ding YJ, et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol. 2008:127:89-97.
37. Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Kremers HM. Trends in incidence of adults - onset psoriasis over three decades: a population-based study. J Am Acad Dermatol. 2009;60:394-401.
38. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population based study. Arhritis Rheum. 2009;61:233-239.
39. Pietrzak A, Chodorowska G, Szepietowski J, Zalewska-Janowska A, Krasowska D, Hercogova J. Psoriasis and serum lipid abnormalities. Dermatol Ther. 2010;23:160-173.
40. Pietrzak A, Jastrzebska I, Krasowska D et al. Serum pancreatic lipase [EC 3.1.1.3] activity, serum lipid profile and peripheral blood dendritic cell populations in normolipidemic males with psoriasis. J Mol Catal B Enzym. 2006;40:144-154.
41. Neinman AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevelance of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829-835.
42. Späh F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol. 2008;159(Suppl 2):10-17.
43. Cohen AD, Gilutz H, Henkin Y et al. Psoriasis and the Metabolic Syndrome. Acta Derm Venereol. 2007;87:506-509.
44. Gisondi P, Tessari G, Conti A et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based casecontrol study. Br J Dermatol. 2007;157:68-73.
45. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298:321-328.
46. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-1428.
47. The IDF consensus worldwide definition of the metabolic syndrome at: http://www.idf.org/webdata/docs/MetSyndrome__FINAL.pdf. Accessed October, 7 2011.
48. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol. 2011;147:419-424.
49. Nisa N, Qazi MA. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol Venereol Leprol. 2010;76:662-665.
50. Mebazaa A, El Asmi M, Zidi W et al. Metabolic syndrome in Tunisian psoriatic patients: prevalence and determinants. J Eur Acad Dermatol Venereol. 2011;25:705-709.
51. Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2010;8:331-334.
52. Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathopysiology. Curr Opin Rheumatol. 2008;20:416-422.
53. Sterry W, Storber BE, Menter A. International Psoriasis Cuncil. Obesity in psoriasis, the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J. Dermatol. 2007;157:649-655.
54. Lindegĺrd B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica. 1986;172:298-304
55. Naldi L, Chatenoud L, Linder D et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005;125:61-67.
56. Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci. 2009;54:1847-1856.
57. Gnacińska M, Małgorzewicz S, Stojek M, Łysiak-Szydłowska W, Sworczak K. Role of adipokines in complications related to obesity: a review. Adv Med Sci. 2009;54:150-157.
58. Chen Y, Wu C, Shen J et al. Psoriasis independently associated with hyperletynemia contributing to metabolic syndrome. Arch Dermatol. 2008;144:1571-1575.
59. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007;380:24-30.
60. Hara K, Boutin P, Mori Y et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes. 2002;51:536-540.
61. Hara K, Horikoshi M, Yamauchi T et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care. 2006;29:1357-1362.
62. Shibata R, Ouchi N, Murohara T. Adiponectin and cardiovascular disease. Circ J. 2009;73:608-614.
63. Gerdes S, Rostami-Yazdi M, Mrowietz U. Adipokines and psoriasis. Exp Dermatol. 2011;20:81-87
64. Shibata R, Sato K, Pimentel DR et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med. 2005;11:1096-1103.
65. Dekker JM, Funahashi T, Nijpels G et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab. 2008;93:1489-1496.
66. Kadowaki T, Yamauchi T, Kubota N. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;106:1784-1792.
67. Targher G, Bertolini L, Scala L. Decreased plasma adiponectin contractions are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol. 2004;61:700-703.
68. Fantuzzi G. Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol. 2008;121:326-330.
69. Takahashi H, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol. 2008;159:1207-1208.
70. Shibata S, Saeki H, Tada Y, Karakawa M, Komine M, Tamaki K. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci. 2009;55: 62-63.
71. Shibata S, Tada Y, Hau C et al. Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy. Br J Dermatol. 2011;164:667-670.
72. Kaur S, Zilmer K, Kairane C, Kals M, Zilmer M. Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br J Dermatol. 2008;159:1364-1367.
73. Coimbra S, Oliveira H, Reis F et al. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol. 2010;24:1386-1394.
74. Wang Y, Chen J, Zhao Y, Geng L, Song F, Chen HD. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol. 2008;158:1134-1135.
75. Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev. 2007;8:21-34.
76. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin - the classical, resistin - the controversical, adiponectin - the promising, and more to come. Best Pract Res Cl En. 2005;19:4525-4546.
77. Poeggeler B, Schulz C, Pappolla MA et al. Leptin and the skin: a new frontier. Exp Dermatol. 2010;19:12-18.
78. El-Haschimi K, Pierroz DD, Hileman SM, Bjřrbaek C, Flier JS. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest. 2000;105:1827-1832.
79. Moran O, Phillip M. Leptin: obesity, diabetes and other peripheral effects - a review. Pediatr Diabetes. 2003;4:101-109.
80. Koh KK, Park SM, Quon MJ. Leptin and cardiovascular disease: response to therapeutic interventions. Circulation. 2008;117:3238-3249.
81. Beltowski J. Leptin and atherosclerosis. Atherosclerosis. 2006;189:47-60.
82. Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol. 2004;44:1819-1824.
83. Johnston A, Arnadottir S, Gudjonsson JE et al. Obesity in psoriasis: Leptin and restin as mediators of cutaneous inflammation. Br J Dermatol. 2008;159:342-351.
84. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;52:722-732.
85. Boehncke S, Thaci D, Beschmann H et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol. 2007;157:1249-1251.
86. Filkova M, Haluzík M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol. 2009;133:157-170.
87. Curat CA, Wegner V, Sengenès C et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 2006;49:744-747.
88. Osawa H, Onuma H, Ochi M et al. Resistin SNP-420 determines its monocyte mRNA and serum levels inducing type 2 diabetes. Biochem Biophys Res Commun. 2005;335:596-602.
89. Minn AH, Patterson NB, Pack S et al. Resistin is expressed in pancreatic islets. Biochem Biophys Res Commun. 2003;310:641-645.
90. Schäffler A, Ehling A, Neumann E et al. Adipocytokines in synovial fluid. JAMA. 2003;290:1709-1710.
91. Yura S, Sagawa N, Itoh H et al. Resistin is expressed in the human placenta. J Clin Endocrinol Metab. 2003;88:1394-1397.
92. Senolt L, Housa D, Vernerova Z et al. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis. 2007;66:458-463.
93. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005;174:5789-5795.
94. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys. Res Commun. 2003;309:286-290.
95. Adeghate E. An update on the biology and physiology of resistin. Cell Mol Life Sci. 2004;61:2485-2496.
96. Rea R, Donnelly R. Resistin: an adipocyte-derived hormone. Has it a role in diabetes and obesity? Diabetes Obes Metab. 2004;6:163-170.
97. Dyck DJ, Heigenhauser GJ, Bruce CR. The role of adipokines as regulators of skeletal muscle fatty acid metabolism and insulin sensitivity. Acta Physiol (Oxf). 2006;186:5-16.
98. McTernan PG, Kusminski CM, Kumar S. Resistin. Curr Opin Lipidol. 2006;17:170-175.
99. Heilbronn LK, Rood J, Janderova L et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab. 2004;89:1844-1848.
100. Savage DB, Sewter CP, Klenk ES et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes. 2001;50:2199-202.
101. Korah TE, Ibrahim HH, Badr EA, ElShafie MK. Serum resistin in acute myocardial infarction patients with and without diabetes mellitus. Postgrad Med J. 2011;87:463-467.
102. Hamminga EA, van der Lely AJ, Neumann HA, Thio HB. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses. 2006;67:768-773.
103. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev. 2005;85:495-522.
104. Gauna C, Delhanty PJ D, Hofland LJ et al. Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. J Clin Endocrinol Metab. 2005;90:1055-1060.
105. Hosoda H, Kojima M, Mizushima T, Shimizu S, Kangawa K. Structural divergence of human ghrelin. Identification of multiple ghrelin-derived molecules produced by post-translational processing. J Biol Chem. 2003;278:64-70.
106. Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem. 2004;50:1511-1525.
107. Pulkkinen L, Ukkola O, Kolehmainen M, Uusitupa M. Ghrelin in Diabetes and Metabolic Syndrome. Int J Pept. 2010;2010:1-11.
108. Pöykkö SM, Kellokoski E, Hörkkö S, Kauma H, Kesäniemi YA, Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes. 2003;52:2546-2553.
109. Barazzoni R, Zanetti M, Ferreira C et al. Relationships between desacylated and acylated ghrelin and insulin sensitivity in the metabolic syndrome. J Clin Endocrinol Metab. 2007;92:3935-3940.
110. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-2556.
111. Fujishima S, Watanabe H, Kawaguch M et al. Involvement of IL-17F via the induction of IL-6 in psoriasis. Arch Dermatol Res. 2010;302:499-505.
112. Pietrzak AT, Zalewska A, Chodorowska G et al. Cytokines and anticytokines in psoriasis. Clin Chim Acta. 2008;394:7-21.
113. Eder K, Baffy N, Falus A, Fulop AK. The major inflammatory mediator interleukin-6 and obesity. Inflamm Res. 2009;58:727-736.
114. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003;24:278-301.
115. Esteve E, Castro A, López-Bermejo A, Vendrell J, Ricart W, Fernandez-Real JM. Serum interleukin-6 correlates with endothelial dysfunction in healthy men independently of insulin sensitivity. Diabetes Care. 2007;30:939-945.
116. Nishida M, Moriyama T, Ishii K et al. Effects of IL-6, adiponectin, CRP and metabolic syndrome on subclinical atherosclerosis. Clin Chim Acta. 2007;384:99-104.
117. Goodman WA, Levine AD, Massai JV, Sugiyama H, McCornick TS, Cooper KD. IL-6 Signaling in Psoriasis Prevents Immune Suppression by Regulatory T Cells. J Immun. 2009;183:3170-3176.
118. Sakai R, Matsui S, Fukushima M, Yasuda H, Miyauchi H, Miyachi Y. Prognostic factor analysis for plaque psoriasis. Dermatology. 2005;211:103-106.
119. Kaur S, Zilmer K, Leping V, Zilmer M. The levels of adiponectin and leptin and their relation to other markers of cardiovascular risk in patients with psoriasis. J Eur Acad Dermatol Venereol. 2011;25:1328-1333.
120. Aksentijevich I, Masters SL, Ferguson PJ et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med. 2009;360:2426-2437.
121. Cunliffe WJ, Holland DB, Clark SM, Stables GI. Comedogenesis: some aetiological, clinical and therapeutic strategies. Dermatology. 2003;206:11-16.
122. Yu R, Kim CS, Kawada T, Kwon TW, Lim TH, Kim YW, Kwon BS. Involvement of leukotactin-1, a novel CC chemokine, in human atherosclerosis. Atherosclerosis. 2004;174:35-42.
123. Shin MJ, Lee KH, Chung JH et al. Circulating IL-8 levels in heart failure patients with and without metabolic syndrome. Clin Chim Acta. 2009;405:139-142.
124. Gerhardt CC, Romero IA, Cancello R, Camoin L, Strosberg AD. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol Cell Endocrinol. 2001;175:81-92.
125. Kobashi C, Asamizu S, Ishiki M et al. Inhibitory effect of IL-8 on insulin action in human adipocytes via MAP kinase pathway. J Inflamm (Lond). 2009;27:25.
126. Pietrzak A, Kozioł-Montewka M, Lecewicz-Toruń B, Krasowska D. Is there any correlation between the total number of neutrophils in plasma and concentration of interleukin-8 in psoriatic patients? Med Sci Monit. 2000;6:867-870.
127. Coimbra S, Oliveira H, Reis F et al. Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-a levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol. 2010;163:1282-1290.
128. Takahashi H, Tsuji H, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin Exp Dermatol. 2010;35:645-649.
129. Ozawa M, Terui T, Tagami H. Localization of IL-8 and complement components in lesional skin of psoriasis vulgaris and pustulosis palmaris et plantaris. Dermatology. 2005;211:249-255.
130. Esposito K, Nappo F, Giugliano F et al. Cytokine Milieu Tends Toward Inflammation in Type 2 Diabetes. Diabetes Care. 2003;26:51647.
131. Ware CF. The TNF Superfamily - 2008. Cytokine Growth Factor Rev. 2008;19:183-186.
132. Yamaguchi K, Higashiura K, Ura N et al. The effect of tumor necrosis factor-alpha on tissue specificity and selectivity to insulin signaling. Hypertes Res. 2003;26:389-396.
133. Ruan H, Miles PD, Ladd CM et al. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. Diabetes. 2002;51:3176-3188.
134. Cai D, Yuan M, Frantz DF et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005;11:183-190.
135. Wei Y, Chen K, Whaley-Connel AT, Ibdah JA, Sowers JR. Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. AJP-Regu Physiol. 2008;294:673-680.
136. Shin JY, Kim SY, Jeung MJ et al. Serum adiponectin, C-reactive protein and TNF-alpha levels in obese Korean children. J Pediatr Endocrinol Metab. 2008;21:23-29.
137. Marques-Vidal P, Bochud M, Bastardot F et al. Association between inflammatory and obesity markers in a Swiss population- based sample (CoLaus study). Endokrinologie und Metabolismus 79. Jahrestagung der Schweizerischen Gesellschaft für Innere Medizin Palais de Beaulieu, Lausanne 11.05.2011-13.05.2011. Abstract.
138. Dinh W, Füth R, Nickl W et al. Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. Cardiovasc Diabetol. 2009;8:58.
139. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF- -alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005;2005:273-279.
140. Saraceno R, Schipani C, Mazzotta A et al. Effect of anti- -tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res. 2008;57:290-295.
141. Briot K, Garnero P, Le Henanff A, Dougados M, Roux C. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor alpha treatment. Ann Rheum Dis. 2005;64:1137-1140.
142. Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol. 2008;22:341-344.
143. Nakajima H, Nakajima K, Tarutami M, Morishige R, Sano S. Kinetics of circulating Th17 cytokines and adipokines in psoriasis patients. Arch Dermatol Res.2011;303:451-455.
144. Yamada H. Current perspectives on the role of IL-17 in autoimmune disease. J In Xamm Res. 2010;3:33-44.
145. Hwang SY, Kim JY, Kim KW et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther. 2004;6:120-128.
146. Lubberts E. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine. 2008;41:84-91.
147. Witowski J, Ksiazek K, Jorres A. Interleukin 17: a mediator of inflammatory responses. Cell Mol Life Sci. 2004;61:567-579.
148. Albanesi C, Scarponi C, Cavani A, Federici M, Nasorri F, Girolomoni G. Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and in terleukin-4-induced activation of human keratinocytes. J Invest Dermatol. 2000;115:81-87.
149. Sumarac-Dumanovic M, Stevanovic D, Ljubic A. Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int. J. Obes. (Lond). 2009;33:151-156.
150. Zúńiga LA, Shen WJ, Joyce-Shaikh B et al. IL-17 regulates adipogenesis, glucose homeostasis, and obesity. J Immunol. 2010;185:6947-6959.
151. Arababadi MK, Nosratabadi R, Hassanshahi G et al. Nephropathic complication of type-2 diabetes is following pattern of autoimmune diseases? Diabetes Res Clin Pract. 2010;87:33-37.
152. Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN, Rutledge JC. A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp Dermatol. 2011;20:544-549.
153. Hashmi S, Zeng QT. Role of interleukin-17 and interleukin- -17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis. 2006;17:699-706.
154. Jafarzadeh A, Esmaeeli-Nadimi A, Nough H, Nemati M, Rezayati MT. Serum levels of interleukin (IL)-13, IL-17 and IL-18 in patients with ischemic heart disease. Anadolu Kardiyol Derg. 2009;9:75-83.
155. Surendar J, Aravindhan V, Rao MM, Ganesan A, Mohan V. Decreased serum interleukin-17 and increased transforming growth factor-b levels in subjects with metabolic syndrome (Chennai Urban Rural Epidemiology Study-95). Metabolism. 2011;60:586-590.
156. Lin AM, Rubin CJ, Khandpur R et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187:490-500.
157. Zaba LC, Suarez-Farińas M, Fuentes-Duculan J et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol. 2009;124:1022-1030.
158. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin- 18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 2001;12:53-72.
159. Ericson P, Lindén A, Riise GC. BAL levels of interleukin-18 do not change before or during acute rejection in lungtransplant recipients. Respir Med. 2004;98:159-163.
160. Weiss TW, Seljeflot I, Hjerkinn EM, Arnesen H. Adipose tissue pro-inflammatory gene expression is associated with cardiovascular disease. Int J Clin Pract. 2011;65:939-944.
161. Skurk T, Kolb H, Müller-Scholze S, Röhrig K, Hauner H, Herder C. The proatherogenic cytokine interleukin-18 is secreted by human adipocytes. Eur J Endocrinol. 2005;152:863-868.
162. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008;54:24-38.
163. Mallat Z, Corbaz A, Scoazec A et al. Expression of interleukin- 18 in human atherosclerotic plaques and relation to plaque instability. Circulation. 2001;104:1598-1603.
164. Blankenberg S, Luc G, Ducimetičre P et al; PRIME Study Group. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation. 2003;108:2453-2459.
165. Blankenberg S, Tiret L, Bickel C et al. AtheroGene Investigators. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002;106:24-30.
166. Thorand B, Kolb H, Baumert J et al. Elevated levels of interleukin- 18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984-2002. Diabetes. 2005;54:2932-2938.
167. Hung J, McQuillan BM, Chapman CM, Thompson PL, Beilby JP. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol. 2005;25:1268-1273.
168. Sun L, Hu FB, Yu Z et al. Lean body mass, interleukin 18, and metabolic syndrome in apparently healthy Chinese. PLoS One. 2011;6:e18104.
169. McKenzie RC, Boyce F, Szepietowski J et al. Psoriatic epidermis expresses high levels of Interleukin 18 (IL-18), IL-18 receptor mRNA and IL-18 protein. Derm Klin. 2002;4:17-23.
170. Pietrzak A, Lecewicz-Toruń B, Roliński J. Interleukin-18 serum concentration in patients with psoriasis triggered by infection. Ann Univ Mariae Curie Sklodowska Med. 2002;57:484-490.
171. Pietrzak A, Lecewicz-Torun B, Chodorowska G, Roliński J. Interleukin-18 levels in the plasma of psoriatic patients correlate with the extent of skin lesions and the PASI score. Acta Dermato-Venereologica. 2003;83:262-265.
172. Pietrzak A, Roliński J, Junak-Bojarska A et al. Plasma level of interleukin 18 in psoriatic patients during topical treatment. Derm Klin. 2004;6:75-78.
173. Flisiak I, Zaniewski P, Chodynicka B. Plasma TGF-beta1, TIMP-1, MMP-1 and IL-18 as a combined biomarker of psoriasis activity. Biomarkers. 2008;13:549-556.
174. Companjen AR, van der Velden VH, Vooys A, Debets R, Benner R, Prens EP. Human keratinocytes are major producers of IL-18: predominant expression of the unprocessed form. Eur Cytokine Netw. 2000;11:383-390.
175. van de Kerkhof PC. Novel biologic therapies in development targeting IL-12/IL-23. J Eur Acad Dermatol Venereol. 2010;24(Suppl 6):5-9.
176. Sato K, Suematsu A, Okamoto K et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006;203:2673-2682.
177. Yago T, Nanke Y, Kawamoto M et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther. 2007;9:R96.
178. Wiekowski MT, Leach MW, Evans EW et al. Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J Immunol. 2001;166:7563-7570.
179. Nakajima K, Kanda T, Takaishi M et al. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J Immunol. 2011;186:4481-4489.
180. Maedler K, Dharmadhikari G, Schumann DM, Størling J. Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes. Handb Exp Pharmacol. 2011;203:257-278.
181. Jager J, Grémeaux T, Cormont M, Le Marchand-Bruste Y, Tanti JF. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate- 1 expression. Endocrinology. 2007;148:241-251.
182. Juge-Aubry CE, Somm E, Chicheportiche R et al. Regulatory effects of interleukin (IL)-1, interferon-β, and IL-4 on the production of IL-1 receptor antagonist by human adipose tissue. J Clin Endocrinol Metab. 2004:89:2652-2658.
183. Spranger J, Kroke A, Möhlig M et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52:812-817.
184. Annecke K, Schmitt M, Euler U et al. uPA and PAI in breast cancer: review of their clinical utility and current validation in the prospective NNBC -3 trial. Adv Clin Chem. 2008;45:31-45.
185. Binder BR, Christ G, Gruber F et al. Plasminogen Activator Inhibitor 1: Physiological and Pathophysiological Roles. News Physiol Sci. 2002;17:56-61.
186. Trost S, Pratley R, Sobel B. Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes. Curr Diab Rep. 2006;6:47-54.
187. Black PH, Garbutt LD. Stress, inflammation and cardiovascular disease. J Psychosom Res. 2002;52:1-23.
188. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Insulin Resistance Atherosclerosis Study. Elevated levels of acutephase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51:1131-1137.
189. Nielsen HJ, Christensen IJ, Svendsen MN et al. Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res. 2002;51:563-567.
190. Vanizor Kural B, Orem A, Cimşit G, Uydu HA, Yandi YE, Alver A. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clin Chim Acta. 2003;332:23-30.
191. Alessi MC, Bastelica D, Morange P et al. Plasminogen activator inhibitor 1, transforming growth factor-beta 1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes. 2000;49:1374-1380
192. Segarra A, Chacón P, Martinez-Eyarre C et al. Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: biochemical correlations and role as independent predictors of coronary artery stenosis. J Am Soc Nephrol. 2001;12:1255-1263.
193. Kralisch S, Sommer G, Deckert CM et al. Adipokines in diabetes and cardiovascular diseases. Minerva Endocrinol. 2007;32:161-171.
194. Liu H, Hu Y, Simpson RW, Dear AE. Glucagon-like peptide- 1 attenuates tumour necrosis factor-alpha-mediated induction of plasminogen [corrected] activator inhibitor-1 expression. J Endocrinol. 2008;196:57-65.
195. Hamaguchi E, Takamura T, Shimizu A, Nagai Y. Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. J Pharmacol Exp Ther. 2003;307:987-994.
196. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811-1821
197. Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol. 2005;25:1038-1044.
198. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR et al. Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum. 2009;39:157-162.
199. Yoo TW, Sung KC, Shin HS. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J. 2005;69:928-933.
200. Lin SD, Tsai DH, Hsu SR. Association between serum uric acid level and components of the metabolic syndrome. J Chin Med Assoc. 2006;69:512-156.
201. Kwon HH, Kwon IH, Choi JW, Youn JI. Cross-sectional study on the correlation of serum uric acid with disease severity in Korean patients with psoriasis. Clin Exp Dermatol. 2011;36:473-478.
202. Isha V K, Lal J, Lal H. C-reactive protein and uric acid levels in patients with psoriasis. Ind J Clin Biochem. 2011;26:309-311.
203. Prasad PV, Bikku B, Kaviarasan PK, Senthilnathan A. A clinical study of psoriatic arthropathy. Indian J Dermatol Venereol Leprol. 2007;73:166-170
204. Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC. Lipid disturbances in psoriasis: an update. Mediators Inflamm. 2010;2010:535612.
205. Mallbris L, Granath F, Hamsten A, Ståhle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006;54:614-621.
206. Frank PG, Marcel YL. Apolipoprotein A-1: structure-function relationship. J Lipid Res. 2000;41:853-872.
207. Wilhelm AJ, Zabalawi M, Owen JS et al. Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr-/-, ApoA-I-/- mice. J Biol Chem. 2010;285:36158-36169.
208. Tekin NS, Tekin IO, Barut F, Sipahi EY. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm. 2007;2007:78454.
209. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clinica Chimica Acta. 2001;303:33-39.
210. Piskin S, Gurkok F, Ekuklu G, Senol M. Serum lipid levels in psoriasis. Yonsei Med J. 2003;44:24-26.
211. Vanizor Kural B, Örem A, Çimşit GU, Yandi YE, Calapoglu M. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clinica Chimica Acta. 2003;328:71-82.
212. Hadas E, Bozek A, Jarzab J. Impact of phototherapy on selected lipid profile indices in psoriatic patients allowing for intensification of the disease. Post Dermatol Alergol. 2007;24:215-223.
213. Wharton D, Gharavi N, Navab M, Lee S, Berliner J, Fogelman A, Modlin R. Role of host lipid metabolism and tissue macrophages in psoriasis. J Immunol April. 2011;186:(Meeting Abstract Supplement)147.30.
214. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;101:1805-1812.
215. Ridker PM. C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. Clin Chem. 2009;55:209-215.
216. Yeh ETH, Palusinski RP. C-reactive protein: the pawn has been promoted to queen. Curr Atheroscler Rep. 2003;5:101-105.
217. Coimbra S, Oliveira H, Reis F et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol. 2010;24:789-796.
218. Kanelleas A, Liapi C, Katoulis A et al. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept. Clin Exp Dermatol. 2011 Jul 25. Epub ahead of print.
219. Coimbra S, Oliveira H, Reis F et al. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study. Am J Clin Dermatol. 2010;11:423-432.
220. Yiu KH, Yeung CK, Chan HT et al. Increased arterial stiffness in patients with psoriasis is associated with active systemic inflammation. Br J Dermatol. 2011;164:514-520.
221. Ludwig RJ, Herzog C, Rostock A et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007;156:271-276.